Literature DB >> 7161613

Confusion, dementia and anticholinergics in Parkinson's disease.

Y de Smet, M Ruberg, M Serdaru, B Dubois, F Lhermitte, Y Agid.   

Abstract

Among a population of 75 hospitalised Parkinsonian subjects, confusional states were observed in 46% of demented patients not receiving anticholinergic drugs and in 93% of demented patients under anticholinergic therapy. The sensitivity of demented Parkinsonians to anticholinergic drugs can be attributed to a cholinergic deficiency which has been detected in the cortex and hippocampus of Parkinsonian patients post-mortem. The observations suggest that anticholinergic medication should be avoided in Parkinsonians with intellectual impairment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7161613      PMCID: PMC491705          DOI: 10.1136/jnnp.45.12.1161

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  29 in total

1.  COGNITIVE AND PERCEPTUAL PERFORMANCE IN PARKINSONISM AS A FUNCTION OF AGE AND NEUROLOGICAL IMPAIRMENT.

Authors:  E LEVITA; M RIKLAN; I S COOPER
Journal:  J Nerv Ment Dis       Date:  1964-12       Impact factor: 2.254

2.  Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment.

Authors:  J V Beardsley; F Puletti
Journal:  Arch Neurol       Date:  1971-08

3.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

4.  Cerebral atrophy in Parkinsonism.

Authors:  G Selby
Journal:  J Neurol Sci       Date:  1968 May-Jun       Impact factor: 3.181

5.  Psychiatric disturbances in Parkinson's disease.

Authors:  G G Celesia; W M Wanamaker
Journal:  Dis Nerv Syst       Date:  1972-09

6.  Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning.

Authors:  A W Loranger; H Goodell; J E Lee; F McDowell
Journal:  Arch Gen Psychiatry       Date:  1972-02

7.  Psychiatric symptoms in Parkinsonism.

Authors:  R H Mindham
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-04       Impact factor: 10.154

8.  Reversal of central anticholinergic syndrome in man by physostigmine.

Authors:  R C Duvoisin; R Katz
Journal:  JAMA       Date:  1968-11-25       Impact factor: 56.272

9.  The prevalence, natural history and dementia of Parkinson's disease.

Authors:  M Pollock; R W Hornabrook
Journal:  Brain       Date:  1966-09       Impact factor: 13.501

10.  Levodopa's awakening effect on patients with Parkinsonism.

Authors:  G G Marsh; C M Markham; R Ansel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

View more
  21 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

Review 2.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

Review 3.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

4.  Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert.

Authors:  T G Aigner; S J Mitchell; J P Aggleton; M R DeLong; R G Struble; D L Price; G L Wenk; M Mishkin
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 5.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

6.  Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients.

Authors:  T S Elizan; H Sroka; H Maker; H Smith; M D Yahr
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

7.  The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.

Authors:  T Prohorov; C Klein; A Miniovitz; E Dobronevsky; J M Rabey
Journal:  J Neurol       Date:  2005-08-17       Impact factor: 4.849

8.  Differing patterns of psychiatric impairment in Alzheimer and demented parkinsonian patients.

Authors:  P Soliveri; M B Zappacosta; L Austoni; P Caffarra; A Scaglioni; D Testa; E Palazzini; T Caraceni; F Girotti
Journal:  Ital J Neurol Sci       Date:  1994-11

Review 9.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

10.  Anticholinergic therapy and dementia in patients with Parkinson's disease.

Authors:  M Pondal; T Del Ser; F Bermejo
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.